Market OpportunitiesMDT has multiple opportunities in high-growth areas like PFA, TAVR, robotic surgery, and renal denervation.
Product Launch And InnovationRecent launches, including Affera in the US, are expected to help improve the stock's performance.
Revenue GrowthMDT recorded its eighth straight quarter of MSD organic sales growth, with F2Q revenue of $8.40B, exceeding the guidance for growth of around 4.5%.